Vasundhara Rasy.

Why is Vasundhara Rasayans Ltd falling/rising?

As of 07-Aug, Vasundhara Rasayans Ltd's stock price is rising at Rs 178.10, with a 2.18% increase and strong performance indicators, despite a decline in investor participation. The stock has gained 4.12% over the last two days and is trading above all key moving averages.

As of 07-Aug, Vasundhara Rasayans Ltd's stock price is rising, currently at Rs 178.10, reflecting a change of 3.8 (2.18%) upward. The stock has shown positive performance today, outperforming its sector by 3.71%. It has been on a consecutive gain streak for the last two days, accumulating a total return of 4.12% during this period. The stock opened with a gain of 2.12% today and reached an intraday high of Rs 182, marking a 4.42% increase.<BR><BR>Additionally, the stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a strong upward trend. However, it is important to note that there has been a decline in investor participation, with delivery volume on 06 Aug falling by 53.32% compared to the 5-day average. Despite this drop in participation, the overall positive price movement and performance metrics suggest that the stock is currently experiencing a rise.

Which are the latest news on Vasundhara Rasy.?

When is the next results date for Vasundhara Rasayans Ltd?

The next results date for Vasundhara Rasayans Ltd is 14 August 2026.

The next results date for Vasundhara Rasayans Ltd is scheduled for 14 August 2026.

Should I buy, sell or hold Vasundhara Rasayans Ltd?

How big is Vasundhara Rasy.?

As of 10th June, Vasundhara Rasayans Ltd has a market capitalization of 52.00 Cr, with recent net sales of 31.59 Cr and a net profit of 3.80 Cr.

As of 10th June, Vasundhara Rasayans Ltd has a market capitalization of 52.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 31.59 Cr and a Net Profit of 3.80 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 35.56 Cr and Total Assets of 43.07 Cr.

Who are in the management team of Vasundhara Rasy.?

The management team of Vasundhara Rasy includes Sunil Jain Kumar, Sanjoy Kumar Jain, Rajesh Pokerna, Seema Jain, Manish Kumar Jain as Whole Time Directors, along with independent directors Pradeep Kumar Jain, Pravichandra Majumdar Popatlal, Rajiv Kakodkar, Manish Jain, and Ashish Kedia. This team combines executive leadership with independent oversight.

The management team of Vasundhara Rasy includes the following individuals:<BR><BR>1. **Sunil Jain Kumar** - Executive Director / Whole Time Director<BR>2. **Sanjoy Kumar Jain** - Executive Director & Whole Time Director<BR>3. **Rajesh Pokerna** - Executive Director & Managing Director<BR>4. **Seema Jain** - Executive Director & Whole Time Director<BR>5. **Pradeep Kumar Jain** - Independent Non-Executive Director<BR>6. **Pravichandra Majumdar Popatlal** - Independent Non-Executive Director<BR>7. **Rajiv Kakodkar** - Independent Non-Executive Director<BR>8. **Manish Jain** - Independent Director<BR>9. **Ashish Kedia** - Independent Director<BR>10. **Manish Kumar Jain** - Whole-time Director<BR><BR>This team brings a mix of executive and independent oversight to the company's operations.

Who are the peers of the Vasundhara Rasy.?

Peers of Vasundhara Rasy. include Sunil Healthcare, Samrat Pharma, Biofil Chemicals, Asston Pharmaceu, Kabra Drugs, Vivo Bio Tech, Shelter Pharma, Veerhealth Care, Rajnish Wellness, and Vista Pharma. Management risk varies from excellent at Samrat Pharma and Shelter Pharma to below average at others, with Kabra Drugs showing the highest 1-year return at 86.81% and Rajnish Wellness the lowest at -53.26%.

Peers: The peers of Vasundhara Rasy. are Sunil Healthcare, Samrat Pharma, Biofil Chemicals, Asston Pharmaceu, Kabra Drugs, Vivo Bio Tech, Shelter Pharma, Veerhealth Care, Rajnish Wellness, and Vista Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Samrat Pharma and Shelter Pharma, while Average management risk is found at Asston Pharmaceu, and Rajnish Wellness, and the rest. Below Average management risk is noted at Sunil Healthcare, Biofil Chemicals, Kabra Drugs, Vivo Bio Tech, Veerhealth Care, and Vista Pharma. Growth is Excellent at Kabra Drugs, Good at Sunil Healthcare and Shelter Pharma, Average at Veerhealth Care, and Below Average at Samrat Pharma, Biofil Chemicals, Asston Pharmaceu, Vivo Bio Tech, Rajnish Wellness, and Vista Pharma. Capital Structure is Excellent at Samrat Pharma and Shelter Pharma, Good at Biofil Chemicals, Vasundhara Rasy., and Veerhealth Care, Average at Asston Pharmaceu, and Below Average at Sunil Healthcare, Kabra Drugs, Vivo Bio Tech, Rajnish Wellness, and Vista Pharma.<BR><BR>Return Snapshot: Kabra Drugs has the highest 1-year return at 86.81%, while Rajnish Wellness has the lowest at -53.26%, with Vasundhara Rasy.'s own 1-year return at -26.10% being higher than Rajnish Wellness but lower than Kabra Drugs. Additionally, the six-month return is negative for Sunil Healthcare, Samrat Pharma, Biofil Chemicals, Asston Pharmaceu, Vivo Bio Tech, and Rajnish Wellness.

What does Vasundhara Rasy. do?

Vasundhara Rasayans Ltd is a manufacturer and exporter of antacid Active Pharmaceutical Ingredients in the pharmaceuticals sector, with a market cap of INR 52 Cr and reported net sales of 7 Cr and net profit of 1 Cr for December 2025. The company has a P/E ratio of 13.00 and a dividend yield of 1.23%.

Overview:<BR>Vasundhara Rasayans Ltd is a leading manufacturer and exporter of antacids therapeutic category Active Pharmaceutical Ingredients, operating in the Pharmaceuticals & Biotechnology industry within the micro-cap market.<BR><BR>History:<BR>The company was incorporated in March 1987 and began operations in 1990 with an Antacid API facility. The latest quarterly results reported net sales and profit for December 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 7 Cr (Quarterly Results - Dec 2025) <BR>Net Profit: 1 Cr (Quarterly Results - Dec 2025) <BR>Market-cap: INR 52 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 13.00 <BR>Industry P/E: 42 <BR>Dividend Yield: 1.23% <BR>Debt-Equity: -0.04 <BR>Return on Equity: 10.69% <BR>Price to Book: 1.45 <BR><BR>Contact Details:<BR>Address: Shed No 42 Phase II IDA, Mallapur Hyderabad Telangana : 500076 <BR>Tel: 91-40-23437617/23437623 <BR>Email: info@vrlindia.in <BR>Website: http://www.vasundhararasayans.in

Are Vasundhara Rasayans Ltd latest results good or bad?

Vasundhara Rasayans Ltd's latest results show strong profit growth with a 261.40% increase in net profit to ₹2.06 crores and an improved operating margin of 24.04%. However, revenue declined by 9.82% year-on-year to ₹8.82 crores, indicating challenges despite the positive profit performance.

The latest results for Vasundhara Rasayans Ltd present a mixed picture. On one hand, the company reported a significant increase in net profit for Q2 FY26, reaching ₹2.06 crores, which is a remarkable 261.40% increase quarter-on-quarter. This improvement is accompanied by a strong operating margin of 24.04%, a substantial rise from just 4.23% in the previous quarter. <BR><BR>However, the revenue figures tell a different story. The company generated ₹8.82 crores in revenue for Q2 FY26, which represents a 9.82% decline compared to the same quarter last year. While there was a sequential growth of 16.67% from the previous quarter, the year-on-year drop raises concerns about the sustainability of this growth.<BR><BR>Overall, while the profit margins and operational efficiency have improved significantly, the decline in revenue indicates underlying challenges that the company faces. This combination of strong profit growth alongside stagnating revenue suggests that while there are positive aspects, there are also serious concerns that need to be addressed. Therefore, the results can be seen as good in terms of profitability but bad in terms of revenue growth, reflecting a complex situation for the company.

Is Vasundhara Rasy. overvalued or undervalued?

As of December 4, 2025, Vasundhara Rasy. is considered overvalued with a valuation grade of "expensive," a PE Ratio of 13.42, and a year-to-date return of -35.36%, significantly lagging behind its peers and the Sensex.

As of 4 December 2025, the valuation grade for Vasundhara Rasy. has moved from very expensive to expensive, indicating a shift in perception regarding its market valuation. The company is currently considered overvalued. Key ratios include a PE Ratio of 13.42, an EV to EBITDA of 14.79, and a ROE of 12.74%. <BR><BR>In comparison to peers, Vasundhara Rasy.'s PE Ratio is significantly lower than Solar Industries, which has a PE of 88.66, and Gujarat Fluoroch at 54.14. While Vasundhara Rasy. shows a PEG Ratio of 0.00, indicating no growth expectations, its current valuation does not align favorably with its peers in the Pharmaceuticals & Biotechnology sector. Additionally, the company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -35.36% compared to the Sensex's 9.12%, further reinforcing the overvaluation narrative.

How has been the historical performance of Vasundhara Rasy.?

Vasundhara Rasy has experienced fluctuating net sales and profits, peaking at 37.94 Cr in Mar'23 but declining to 33.99 Cr by Mar'25, alongside a decrease in profitability and negative cash flow trends. Despite an increase in total assets and liabilities, the company's operating profit margin and overall profitability have faced significant challenges.

Answer:<BR>The historical performance of Vasundhara Rasy shows a fluctuating trend in net sales and profits over the years, with a notable decline in recent periods.<BR><BR>Breakdown:<BR>Vasundhara Rasy's net sales peaked at 37.94 Cr in Mar'23 but fell to 33.99 Cr by Mar'25. The total operating income followed a similar trend, decreasing from 37.94 Cr in Mar'23 to 33.99 Cr in Mar'25. The raw material costs have remained relatively stable, with a slight increase from 15.53 Cr in Mar'24 to 15.63 Cr in Mar'25. Operating profit (PBDIT) also declined from 8.33 Cr in Mar'24 to 6.40 Cr in Mar'25, reflecting a decrease in operating profit margin from 17.26% to 11.92%. Profit before tax decreased from 7.90 Cr in Mar'24 to 5.77 Cr in Mar'25, while profit after tax dropped from 5.86 Cr to 4.25 Cr in the same period. The company's total assets increased from 37.30 Cr in Mar'24 to 43.07 Cr in Mar'25, alongside a rise in total liabilities from 37.30 Cr to 43.07 Cr. Cash flow from operating activities showed a negative trend, with a cash outflow of 5.00 Cr in Mar'25 compared to an inflow of 6.00 Cr in Mar'24. Overall, while Vasundhara Rasy has seen growth in total assets, its profitability and cash flow have faced challenges in recent years.

What is the technical trend for Vasundhara Rasy.?

As of May 23, 2025, Vasundhara Rasy's technical trend has shifted to a moderate bearish stance, supported by bearish signals from key indicators like the MACD, Bollinger Bands, and moving averages, along with significant underperformance compared to the Sensex.

As of 23 May 2025, the technical trend for Vasundhara Rasy has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this assessment include the weekly MACD and Bollinger Bands both indicating bearish conditions, along with daily moving averages also showing bearish signals. The KST is bearish on a weekly basis and mildly bearish monthly, while Dow Theory reflects a mildly bearish stance on the weekly and monthly time frames. The stock has underperformed significantly compared to the Sensex over various periods, particularly year-to-date and over the past year.

Who are the top shareholders of the Vasundhara Rasy.?

The top shareholder of Vasundhara Rasy is P & J Cretechem Private Limited, holding 61.98%, followed by Garg Leasing And Finance Private Limited at 3.55%, while individual investors own 30.05%. There are no mutual funds or foreign institutional investors in the company.

The top shareholders of Vasundhara Rasy include P & J Cretechem Private Limited, which holds the largest stake at 61.98%. The highest public shareholder is Garg Leasing And Finance Private Limited, with a holding of 3.55%. Additionally, individual investors collectively own 30.05% of the company. There are no mutual funds or foreign institutional investors currently holding shares in Vasundhara Rasy.

Has Vasundhara Rasy. declared dividend?

Vasundhara Rasayans Ltd has declared a 20% dividend, amounting to ₹2 per share, with an ex-date of September 23, 2024. While the stock has shown strong long-term gains, recent performance reflects negative returns in the short term, and the dividend yield is relatively low at 0.98%.

Vasundhara Rasayans Ltd has declared a 20% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 20%<BR>- Amount per share: 2<BR>- Ex-date: 23 Sep 24<BR><BR>Dividend Yield: 0.98%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -27.93%, with a dividend return of 0%, resulting in a total return of -27.93%.<BR><BR>Over the past year, the price return was -7.7%, the dividend return was 0.87%, leading to a total return of -6.83%.<BR><BR>In the 2-year period, the price return was 30.53%, the dividend return was 2.57%, culminating in a total return of 33.1%.<BR><BR>During the last 3 years, the price return was 77.1%, with a dividend return of 4.75%, resulting in a total return of 81.85%.<BR><BR>For the 4-year period, the price return was 112.13%, the dividend return was 5.39%, which led to a total return of 117.52%.<BR><BR>In the 5-year span, the price return was 479.66%, with a dividend return of 16.81%, resulting in a total return of 496.47%.<BR><BR>Overall, while Vasundhara Rasayans Ltd has declared a dividend, the recent total returns indicate a mixed performance, with significant gains over longer periods but negative returns in the short term. The dividend yield is relatively low, suggesting that while dividends are being paid, the stock may not be performing strongly in the short run.